• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Major birth defects and chromosomal abnormalities significantly associated with increased cancer risk

byDavy LauandAlex Chan
December 10, 2020
in Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The association between major birth defects and cancer risk was present in children, adolescents, and adults, although the risk was lower in adults.

2. Chromosomal abnormalities were associated with a 5.5 times higher risk of cancer, compared to 1.5 times greater risk for non-chromosomal abnormalities.

Evidence Rating Level: 3 (Average)

Birth defects have consistently been shown to be one of the strongest predictors of childhood cancers. However, very little research has been conducted on whether this association continues for cancer in adulthood. The current study was a case-control examining the association between different types of birth defects and cancer risk in children, adolescents, and adults. The study population consisted of individuals from 4 Nordic countries: Norway, Sweden, Finland, and Denmark. There were 62,295 cases (individuals with a cancer diagnosis) and 724,542 controls (living individuals with no cancer diagnosis): The controls were matched to cases by country and year of birth in a 1:10 ratio. Overall, the study found that 3.5% of cases and 2.2% of controls had major birth defects. The odds ratio for overall cancer risk in those with major birth defects compared to those without, was 1.74 (99% CI 1.63-1.84). The risk was greater for individuals with chromosomal abnormalities compared to non-chromosomal abnormalities (OR 5.53, 99% CI 4.67-6.54 and OR 1.54, 99% CI 1.44-1.64 respectively). Furthermore, although the risk for cancer was elevated in all age groups, the risk was lower in adults (20 years of age and older) than in adolescents and children (15-19 years and 0-14 years respectively). For instance, in adults with non-chromosomal abnormalities, the OR was 1.21 (99% CI 1.09-1.33) compared to 1.58 (99% CI 1.31-1.90) in adolescents and 2.03 (99% CI 1.85-2.23) in children. In conclusion, the elevated risk for developing cancer persists through to adulthood, although the risk is lower compared to childhood.

Click to read the study in BMJ

Image: PD

RELATED REPORTS

Pfizer’s Talzenna combo significantly delays prostate cancer progression

2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

Dipeptidyl peptidase-4 inhibitors may be associated with an increased incidence of malignancy

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: geneticsoncology
Previous Post

#VisualAbstract: Acamprosate found an effective and tolerable interventions for alcohol dependence

Next Post

Weekly selinexor, bortezomib, and dexamethasone demonstrates improved survival in treatment-refractory multiple myeloma

RelatedReports

Radiation plus hormone therapy may improve prostate cancer survival
Oncology

Pfizer’s Talzenna combo significantly delays prostate cancer progression

April 9, 2026
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Endocrinology

2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

March 30, 2026
Intrapartum serum prolactin may predict risk of postpartum diabetes
Chronic Disease

Dipeptidyl peptidase-4 inhibitors may be associated with an increased incidence of malignancy

March 26, 2026
High frequency of germline mutations observed in triple negative breast cancers
The Scan by 2 Minute Medicine®

Susie Wiles’ breast cancer diagnosis drives national screening surge

March 25, 2026
Next Post
The STORM trial: treatment refractory multiple myeloma patients experience response with selinexor

Weekly selinexor, bortezomib, and dexamethasone demonstrates improved survival in treatment-refractory multiple myeloma

#VisualAbstract: Increased incidence of sebaceous carcinomas among solid organ transplant recipients

#VisualAbstract: Increased incidence of sebaceous carcinomas among solid organ transplant recipients

#VisualAbstract Daratumumab, Lenalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Cytogenetic Subgroup Analysis from POLLUX

#VisualAbstract Daratumumab, Lenalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Cytogenetic Subgroup Analysis from POLLUX

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Renal point-of-care ultrasound may be effective at identifying patients with nephrolithiasis
  • Shorter antibiotic courses non-inferior for inpatient community-acquired pneumonia
  • 2 Minute Medicine Rewind April 13, 2026
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

The Classics in Medicine Paperback Released!

Over the past 30 years, the transition from print to digital media has contributed to an exponential increase in medical literature. In response, 2 Minute Medicine presents 160+ authoritative, physician-written summaries of the most cited landmark trials in medicine.

amazon-logo_blackGet-it-on-iBooks-badge

Click anywhere to close this announcement

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.